1 Data from the approval were based on results from the phase 1 TRANSCEND NHL 001 trial (NCT02631044). or liso-cel) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy. In this study of patients with R/R LBCL, administration of liso-cel and monitoring of CAR T-cell therapy-related toxicities was feasible and effective in outpatient settings in nonuniversity medical centers, in addition to inpatient treatment. People who received liso-cel reported side effects that researchers considered to be manageable, and that were known to occur with CAR T cell treatment. Median (range) number of previous lines of therapy was three (1-11) with 30% receiving ≥five previous lines of therapy, 73% of patients were age 65 years and older, 69% had refractory disease, 53% had BTKi refractory disease, 23% had TP53 mutation, and 8% had secondary CNS. Multiple new analyses of the Phase 3 KarMMa-3 study of Abecma ® (idecabtagene vicleucel) in triple-class. Treatment with liso-cel appears to result in clinically meaningful activity across several subgroups of patients with mantle cell lymphoma, including those with high-risk features. Use of liso-cel resulted in a high objective response rate, with a low incidence of grade 3 or worse cytokine release syndrome and neurological events in patients with relapsed or refractory large B-cell lymphomas, including those with diverse histological subtypes and high-risk features. Findings suggest that liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features, who have limited treatment options. Notably, the FDA has granted priority review to the supplemental biologics license application seeking approval to expand the indication of liso-cel to include patients with relapsed/refractory. We aimed to assess the activity and safety of liso-cel in patients with relapsed or refractory large B-cell lymphomas We did a seamless design study at 14 cancer centres in the USA. It consists of autologous T cells that are genetically modified to produce a CAR protein,. [ 1] This study was the broadest and largest among the three pivotal studies. Kids and their devices, am I right? Parents are constantly worryi. Here we report results after ~3-y FU. Liso-cel is an investigational, CD19-directed, defined composition, 4-1BB CAR T cell product administered at equal doses of CD8 + and CD4 + CAR + T cells. Liso-cel is effective in patients with relapsed/refractory CLL, and may address some traditional factors associated with high-risk disease, including prior exposure to BTK inhibitors or BCL-2. Liso-cel is a chimeric antigen receptor (CAR) T-cell therapy that has been shown to be effective in R/R MCL treatment. The FDA has issued an approval to the biologics license application (BLA) for the CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi; liso-cel) in the treatment of adult patients with certain types of large B-cell lymphoma following 2 or more prior therapies. No grade 5 AEs occurred within the first 30 days after liso-cel. Aim: Cost-effectiveness analysis (CEA) was performed to compare axicabtagene ciloleucel (axi-cel) with tisagenlecleucel (tisa-cel) and lisocabtagene (liso-cel) for treatment of relapsed or refractory large B-cell lymphoma in adult patients after ≥2 lines of therapy in Japan. Lisocabtagene maraleucel is a CD19-directed chimeric antigen receptor (CAR) T cell immunotherapy. B-cell aplasia (< 3% CD19 + B cells in peripheral blood lymphocytes) after liso-cel infusion was rapid and maintained in ≥ 95% of pts through Month 2. Introduction The objective of this study was to evaluate the cost-effectiveness of lisocabtagene maraleucel (liso-cel) versus other available chimeric antigen receptor T-cell therapies, including axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), in patients who had received at least two prior therapies from a United States (US) commercial third-party payer perspective A previous MAIC report showed comparable efficacy and an improved safety profile of liso-cel vs axi-cel in 3L+ R/R LBCL (Maloney et al. bobbys department store A seat belt is a safety harness designed to hold you in place in the case of an accident or abrupt stop. Bristol-Meyers Squibb Company announced that the FDA granted a priority review to its BLA for liso-cel to treat patients with relapsed or refractory large B-cell lymphoma. The T cells in a patient's body are collected and genetically re-engineered to become CAR T cells that are administered via infusion as a 1-time treatment The FDA has granted priority review to 2 supplemental biologics license applications (sBLAs) for lisocabtagene maraleucel (liso-cel; Breyanzi) in the management of relapsed/refractory mantle cell lymphoma (MCL) and follicular lymphoma following prior treatment with a Bruton tyrosine kinase (BTK) inhibitor, according to a press release from Bristol Myers Squibb. ブリストル・マイヤーズ スクイブは、2022年12月20日、CD19を標的とするCAR-T細胞療法リソカブタゲン マラルユーセル（liso-cel、製品名：ブレヤンジ）について、自家造血幹細胞移植への適応の有無にかかわらず、再発・難治性の大細胞型B細胞リンパ腫（LBCL）の2次治療として、再生医療等製品製造. Kids and their devices, am I right? Parents are constantly worryi. In addition, Axi-cel and liso-cel demonstrated superior progression-free survival compared to standard salvage chemoimmunotherapy followed by HDT/ASCT for second-line LBCL patients either. Sep 1, 2020 · Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. Three CAR T-cell therapies - axicabtagene cilo-leucel (axi-cel), tisagenlecleucel (tisa-cel), and most recently lisocabtagene maraleucel (liso-cel) - may offer curative poten-tial among patients who have failed curative treatment options in the first- and. How is liso-cel different from other CAR T-cell therapies? Kamdar: Liso-cel is an autologous CD19-directed, defined composition 41BB CAR T-cell product. The FDA has granted approval to lisocabtagene maraleucel (liso-cel; Breyanzi) as a treatment for patients with relapsed/refractory mantle cell lymphoma (MCL), according to a press release from the developers, Bristol Myers Squibb Supporting data for the approval in this indication came from the MCL cohort of the phase 1 TRANSCEND NHL 001. Lisocabtagene maraleucel (liso-cel; Breyanzi) has been granted accelerated approval by the FDA for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received at least 2 prior lines of therapy, including a BCL-2 inhibitor and a BTK inhibitor. Type 1 diabetes is a disorder characte. "Liso-cel is an exciting new and differentiated option for patients in Europe with relapsed or refractory large B-cell lymphoma, offering those with a historically poor prognosis a potentially curative treatment option, and results from TRANSCEND NHL 001 and TRANSCEND WORLD reinforce liso-cel as a valuable treatment for a broad range of. On February 5, 2021, the Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc. May 30, 2024 · Bristol Myers Squibb today announced 1 that FDA has approved lisocabtagene maraleucel (liso-cel, Breyanzi) for the treatment of adults with relapsed or refractory (R/R) mantle cell lymphoma. Medical costs covered in the analysis included CAR T-cell therapy procedures, chemotherapy, stem cell transplant, hospital admissions, ongoing monitoring, management of disease progression, end-of-life care, and treatment. Discover excellent insight into the future of work, provided by job search website Executive Placements. Liso-cel is an autologous CD19-directed, defined composition, 4-1BB CAR T cell product administered at equal target doses of CD8 + and CD4 + CAR + T cells. Second-line therapy with lisocabtagene maraleucel (liso-cel) led to durable responses in patients with relapsed or refractory large B-cell lymphoma who were not intended to undergo hematopoietic stem cell transplantation (HCST), according to a primary analysis of the phase 2 PILOT study (NCT03483103). get dollar50 instantly app Liso-cel production involves purifying CD8 + and CD4 + cells separately before activation and transduction followed by T-cell-specific activation and expansion, which reduces the variability of. PRINCETON, N--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced data from three studies evaluating Breyanzi ® (lisocabtagene maraleucel; liso-cel), including long-term data with three-year follow-up from the Phase 3 TRANSFORM trial of Breyanzi as a second-line treatment in patients with relapsed or refractory large B-cell lymphoma (LBCL), results from a subgroup analysis. Liso-cel is a type of immunotherapy called a chimeric antigen receptor (CAR) T-cell therapy. "We included a wide range of aggressive B-cell lymphoma subtypes, and notably patients who have been. We aimed to assess the activity and safety of liso-cel in patients with relapsed or refractory large B-cell lymphomas We did a seamless design study at 14 cancer centres in the USA. Methods Our systematic review identified studies comparing efficacy and safety outcomes of axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel) and tisagenlecleucel (tisa-cel) trials to salvage chemotherapy cohorts in LBCL patients with ≥2 prior lines of treatment; and an extended evidence network included indirect comparisons comparing CAR T-cell therapies キムリア、イエスカルタに続くCAR-T細胞療法として開発が進むliso-cel（開発コード・JCRA017）。昨年の米国血液学会で発表されたP1試験のデータなどをもとに、先行する2剤との差別化を考えます。 Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US regulator as Breyanzi for certain forms of large B-cell lymphoma Weitere CAR-T-Zelltherapie zugelassen. Jun 27, 2022 · On June 24, 2022, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc. ) for the treatment of adult patients with relapsed or refractory (R/R. Jun 18, 2022 · Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has previously demonstrated efficacy and manageable safety in third-line or later LBCL. Adding Ibrutinib Improves the Efficacy of Liso-Cel in R/R CLL. Some reported toxicities of liso-cel include CRS. Beyond liso-cel, Celgene's pipeline must hit two other milestones: approval of the multiple sclerosis drug ozanimod by the end of 2020 — the FDA has set a March 25, 2020 decision deadline — and approval of another blood cancer CAR-T therapy, i decabtagene vicleucel, by March 31, 2021. Our secondary end points were also consistently in favor of liso-cel. To sync these notes with iOS devices or a M. Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study. at level 1 pretest quizlet MONDAY, March 18, 2024 -- The U Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Although liso-cel-treated patients incurred greater upfront costs, fewer required subsequent therapy, and they accumulated less downstream costs. The FDA has granted accelerated approval to lisocabtagene maraleucel (liso-cel; Breyanzi) as a treatment for adult patients with relapsed/refractory follicular lymphoma following 2 or more prior lines of systemic therapy, according to a news release from the agency. Liso-cel was manufactured in support of the TRANSCEND NHL 001 (NCT02631044) and TRANSCEND CLL 004 (NCT03331198) clinical trials. Bristol Myers Squibb's lisocabtagene maraleucel (liso-cel; Breyanzi), a marketed CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy, has been approved by the European Commission in all EU member states for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal LBCL (PMBCL), and follicular lymphoma grade. Liso-cel is under further evaluation at first relapse in large B-cell lymphomas and as a treatment for. Overall, 48% (n = 12) had high tumor burden and 48% were primary refractory. Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has previously demonstrated efficacy and manageable safety in third-line or later LBCL. In prespecified interim and primary analyses of TRANSFORM (NCT03575351), liso-cel showed significant improvements in efficacy vs SOC in pts with R/R LBCL. The FDA has granted lisocabtagene maraleucel (Breyanzi; liso-cel) approval as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma with primary refractory or early relapse within 12 months of frontline treatment. " Liso-cel significantly improves outcomes in second-line DLBCL. Fifty-four patients comprised the PEAS, with 4 patients having received liso-cel at DL1 and 50 having received it at DL2. Liso-cel is an autologous, CD19-directed CAR T-cell product. B-cell aplasia (< 3% CD19 + B cells in peripheral blood lymphocytes) after liso-cel infusion was rapid and maintained in ≥ 95% of pts through Month 2. Here we report results after ~3-y FU. Here we report results after ~3-y FU. The FDA has granted accelerated approval to lisocabtagene maraleucel (liso-cel; Breyanzi) as a treatment for adult patients with relapsed/refractory follicular lymphoma following 2 or more prior lines of systemic therapy, according to a news release from the agency. Ide-cel, previously known as bb2121, is the one that. Liso-cel is an autologous, CD19-directed, 4-1BB CAR T cell product administered at equal target doses of CD8 + and CD4 + CAR + T cells with demonstrated efficacy and favorable safety in clinical studies. [6] The most common side effects include decreases in neutrophils (a.

Liso-cel is under further evaluation at first relapse in large B-cell lymphomas and as a treatment for. Breyanzi, previously called liso-cel, is cleared for use in adults with certain types of large B-cell lymphoma whose cancer has progressed after at least two prior treatments. 05) when compared with axi-cel. Prodotta da Bristol Myers Squibb, liso-cel è una terapia basata sul processo di ingegnerizzazione dei linfociti T del paziente che, in tal modo, si trovano ad esprimere sulla loro superficie il recettore chimerico CAR diretto contro le cellule tumorali su cui è presente l'antigene CD-19. op naruto fanfiction sasuke bashing Chemotherapy comprised 30 mg/m 2 of fludarabine daily and 300 mg/m 2 cyclophosphamide daily. 9 months of follow up EFS in the liso-cel arm was 29. Jun 27, 2022 · On June 24, 2022, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc. On February 5, 2021, the Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc. or liso-cel) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy. Lisocabtagene maraleucel is a CD19-directed chimeric antigen receptor (CAR) T cell immunotherapy. realradio921 When limited to patients without bridging therapy, differences between trials remained statistically insignificant. "CLL and SLL are currently considered incurable diseases with few treatment options in the relapsed setting that can confer complete responses, something that has historically been associated with improved long-term outcomes. It consists of autologous T cells that are genetically modified to produce a CAR protein,. Additionally, the safety profile for liso-cel continued to be manageable, showing the clinically meaningful value of using this differentiated treatment option for patients with relapsed or refractory follicular lymphoma after failure of front-line therapy. Fifty-four patients comprised the PEAS, with 4 patients having received liso-cel at DL1 and 50 having received it at DL2. Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB costimulated CAR T-cell product administered at equal target doses of CD8 + and CD4 + CAR + T cells. We report on patients (pts) with R/R large B cell NHL treated with liso-cel in the outpatient setting in TRANSCEND NHL 001 (NCT02631044) and two phase 2 studies (≥3rd-line therapy. iu fall break Additionally, the safety profile for liso-cel continued to be manageable, showing the clinically meaningful value of using this differentiated treatment option for patients with relapsed or refractory follicular lymphoma after failure of front-line therapy. Jul 1, 2022 · BREYANZI (lisocabtagene maraleucel) is a new cell-based #GeneTherapy treatment for adult patients with relapsed or refractory of certain types of large-B-cell #lymphoma. Jun 27, 2022 · On June 24, 2022, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc. It consists of autologous T cells that are genetically modified to produce a CAR protein,. Promising outcomes with liso-cel in patients with R/R follicular lymphoma. Although liso-cel-treated patients incurred greater upfront costs, fewer required subsequent therapy, and they accumulated less downstream costs. "[Liso-cel] as a differentiated CD19-directed CAR T cell therapy has already proven to be an important treatment option for patients with relapsed or refractory LBCL after 2 or more lines of.

Sep 1, 2020 · Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. On February 5, 2021, the Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc. Come si legge nel comunicato stampa diramato dall. Background: In the absence of randomized studies directly comparing chimeric antigen receptor T cell therapies, this study used matching-adjusted indirect comparisons (MAIC) to evaluate the comparative efficacy and safety of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory. Mar 15, 2024 · US FDA approves Bristol Myers Squibb’s Breyanzi as the first and only CAR T-cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia. In the study, patients who had a median of three lines of treatment were given liso-cel. 4 months in the standard-of-care arm. Methods: Eligible pts had R/R B-cell NHL, ≥2 prior lines of therapy, and ECOG PS ≤1. Many millennials are saving 15% or more in their 401(k) plans, which puts them on track to a $1 million by retirement. In the liso-cel arm, 63% of patients received bridging therapy while the CAR T-cell therapy was manufactured. Friendship Day activities include creating a toss-and-catch game and making a seed bracelet. The approval request, called a biologics license application (BLA), was taken under priority review by the FDA in February, shortening its expected. Liso-cel had a lower incidence of grade ≥ 3 CRS, grade 3-4 serious infections, and steroid use for management of CRS; however, liso-cel exhibited higher incidence of any-grade CRS, any-grade NEs, and tocilizumab use for CRS management. Two atoms of equal strength will share electrons equally. While the study had three different arms, the results discussed here are for the group that received liso-cel only. These figures indicate that liso-cel is a cost-effective treatment, staying below the $100,000 per QALY threshold. Conclusions: Pts with R/R LBCL were successfully treated with liso-cel in outpt and inpt settings at NMCs and monitored for CAR T cell therapy-related toxicities using SOPs and multidisciplinary teams. Liso-cel (Breyanzi, Bristol Myers Squibb) is now indicated to treat adult patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. 1,2 Ahmed Discusses Why the Wait for Liso-Cel Is Worth It By Targeted Oncology Staff Article. Liso-cel's new Prescription Drug User Fee Act (PDUFA) action date is now Nov. Jul 1, 2022 · BREYANZI (lisocabtagene maraleucel) is a new cell-based #GeneTherapy treatment for adult patients with relapsed or refractory of certain types of large-B-cell #lymphoma. The complete response rate was significantly improved favoring liso-cel with a complete response rate of 74% for liso-cel. Methods: Adults with R/R LBCL after first-line tx were eligible. harford county fire blog Nov 15, 2022 · Results of a prespecified interim analysis of the TRANSFORM study (NCT03575351) demonstrated superior efficacy of liso-cel compared with the SOC of salvage immunochemotherapy (CT) followed by high-dose chemotherapy and ASCT in responders, as 2L treatment for patients (pts) with LBCL primary refractory to or relapsed within 12 months of first. " Liso-cel significantly improves outcomes in second-line DLBCL. The FDA has granted lisocabtagene maraleucel (Breyanzi; liso-cel) approval as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma with primary refractory or early relapse within 12 months of frontline treatment. Liso-cel, an autologous, CD19-directed, 4-1BB CAR T cell product, has demonstrated efficacy in large B-cell lymphoma and CLL/SLL. or liso-cel) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy. 7516 Background: Most pts with MCL relapse after first-line immunochemotherapy, with poor responses to salvage therapy. Jul 1, 2022 · BREYANZI (lisocabtagene maraleucel) is a new cell-based #GeneTherapy treatment for adult patients with relapsed or refractory of certain types of large-B-cell #lymphoma. Conclusions: In this phase 1 study of patients with R/R MCL, treatment with liso-cel was associated with a low incidence of grade ≥3 CRS and NEs, late onset of CRS/NEs, and promising clinical activity. Here we report results after ~3-y FU. Check out the great ta. "Liso-cel is an exciting new and differentiated option for patients in Europe with relapsed or refractory large B-cell lymphoma, offering those with a historically poor prognosis a potentially curative treatment option, and results from TRANSCEND NHL 001 and TRANSCEND WORLD reinforce liso-cel as a valuable treatment for a broad range of. 34 years and gained 3. 64 quality-adjusted. Background. TRANSCEND NHL 001 subgroup analysis found that liso-cel may be more effective for patients with mantle cell lymphoma in earlier lines of treatment. Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB costimulated CAR T-cell product administered at equal target doses of CD8 + and CD4 + CAR + T cells. Liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features. Although liso-cel-treated patients incurred greater upfront costs, fewer required subsequent therapy, and they accumulated less downstream costs. 0 years (range, 49-82). Enduring, rapid responses were achieved with lisocabtagene autoleucel (liso-cel; Breyanzi) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to long-term follow-up data from the phase 1/2 TRANSCEND CLL 004 trial (NCT03331198) presented at the 2024 Tandem Meeting The study participants were all patients with hematologic malignancies treated with either of the three CAR-T cell products (axi-cel, tisa-cel, and liso-cel). wei deng The recommended dose for liso-cel is 90 × 10 6 to 110 × 10 6 CAR-positive T cells with a 1:1 ratio of CD4 and CD8 components. Liso-cel is a chimeric antigen receptor (CAR) T-cell therapy that has been shown to be effective in R/R MCL treatment. During a Case-Based Roundtable® event, Sairah Ahmed, MD, discussed the data behind the use of lisocabtagene maraleucel for patients with diffuse large B-cell lymphoma in the second article of a 2-part series Liso-Cel Shows Encouraging Clinical Activity, Safety in Relapsed/Refractory MCL. Nov 15, 2022 · Results of a prespecified interim analysis of the TRANSFORM study (NCT03575351) demonstrated superior efficacy of liso-cel compared with the SOC of salvage immunochemotherapy (CT) followed by high-dose chemotherapy and ASCT in responders, as 2L treatment for patients (pts) with LBCL primary refractory to or relapsed within 12 months of first. In March 2024, liso-cel was also granted accelerated approval for use in chronic lymphocytic leukemia and small lymphocytic leukemia, which is the first CAR T-cell therapy approved for the. All LBCL pts treated at our center with liso-cel or axi-cel outside of a clinical trial between 1/2018 and 5/2023 were included. 1,2 Patients treated with liso-cel demonstrated an average life expectancy of 5. In June 2022, the FDA extended the indication for lisocabtagene maraleucel (liso-cel) to include adults with large B-lymphoma (LBCL) who have refractory disease or relapse within 12 months of first-line chemoimmunotherapy, as well as transplant-ineligible adults with refractory disease or relapse after first-line chemoimmunotherapy. BREYANZI (lisocabtagene maraleucel) is a new cell-based #GeneTherapy treatment for adult patients with relapsed or refractory of certain types of large-B-cell #lymphoma. Sep 1, 2020 · Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. Liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features. In the absence of a randomized head-to-head trial, an unanchored matching-adjusted indirect comparison was performed to estimate the relative treatment effects of axicabtagene ciloleucel (axi-cel; ZUMA-1) versus lisocabtagene maraleucel (liso-cel; TRANSCEND-NHL-001) for treatment of relapsed/refract … Liso-cel is the third FDA-approved autologous CD19 CAR T cell therapy for the treatment of LBCL, based on the TRANSCEND study.